NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Although Phyllanthus species possess a rich history of ethnomedicinal use, their potential in managing neurodegenerative disorders remains under-explored. This study screened ten Phyllanthus species for antioxidant profiles and monoamine oxidase (MAO) inhibition to identify candidates for neuroprotection. Among the tested species, P. emblica emerged as the most potent candidate, exhibiting superior radical scavenging activity, reducing power, and dual MAO-A/B inhibition. These bioactivities were strongly correlated with its high content of phytoconstituents, including total phenolics, flavonoids, and phenylpropanoids. Notably, P. urinaria displayed distinctive selectivity as an MAO-B inhibitor. In a rotenone-induced Parkinson’s disease (PD) model using SH-SY5Y cells, both species significantly mitigated neurotoxicity by attenuating oxidative stress. Mechanistically, treatments with both Phyllanthus species reduced intracellular reactive oxygen species (ROS) and malondialdehyde (MDA) accumulation while preserving glutathione (GSH) levels and restoring superoxide dismutase (SOD) and catalase activities. Collectively, these findings demonstrate that P. emblica and P. urinaria confer neuroprotection through a multi-target mechanism involving direct antioxidant action, enhancement of endogenous defenses, and enzyme modulation, highlighting their potential as therapeutic agents.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.